NCT06437574View on ClinicalTrials.gov

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

July 16, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

May 31, 2028

Conditions
Prostate Cancer
Interventions
DRUG

Vytorin

Vytorin is a drug combination (Ezetimibe and Simvastatin) that targets the two primary sources of cholesterol, absorption in the gut and synthesis in the liver.

DRUG

Ezetimibe

Ezetimibe is a drug that targets one of the primary sources of cholesterol, absorption in the gut.

Trial Locations (1)

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER